华润双鹤：子公司普瑞巴林原料药获上市批准

Core Viewpoint - China Resources Double Crane Pharmaceutical (600062) announced that its wholly-owned subsidiary, Double Crane Pharmaceutical (Shangqiu) Co., Ltd., received the approval notice for the raw material drug Pregabalin from the National Medical Products Administration [1] Group 1: Product Approval - The raw material drug Pregabalin is used for the treatment of postherpetic neuralgia and fibromyalgia [1] - The new process application for market approval was submitted on July 19, 2023, and received approval on April 7, 2025 [1] Group 2: R&D Investment - The total R&D investment for this raw material drug amounts to RMB 8.44 million [1] Group 3: Market Context - As of the announcement date, there are 31 registered manufacturers of Pregabalin raw material on the CDE raw and auxiliary materials registration information public platform [1] - The raw material drug is currently produced for the company's own use and has not been sold externally [1]